Welcome to our dedicated page for FATE THERAPEUTICS SEC filings (Ticker: FATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on FATE THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into FATE THERAPEUTICS's regulatory disclosures and financial reporting.
Fate Therapeutics, Inc. reported a net loss of $30.2 million for the quarter and $61.4 million for the six months ended June 30, 2026, modestly improved from 2025 as operating expenses declined. Collaboration revenue was $3.4 million for the first half, primarily from its Ono Pharmaceutical arrangement.
Cash, cash equivalents and short-term investments totaled $153.8 million at June 30, 2026, and management expects this to fund operations for at least 12 months. The company used $54.3 million of cash in operating activities in the first half and had total assets of $260.1 million, including significant lease right-of-use assets.
Fate remains a clinical-stage cell therapy company focused on iPSC-derived immunotherapies, with no product sales and an accumulated deficit of $1.6 billion. It continues to fund development through collaborations, notably with Ono, and through CIRM awards for FT819 and FT836, which are currently accounted for as liabilities.
Fate Therapeutics reported second-quarter 2026 results and highlighted progress across its iPSC-derived off-the-shelf CAR T-cell pipeline. The first lupus nephritis patient was dosed in -LN, a Phase 2 potentially registrational trial of FT819, treated as an outpatient with same-day discharge, and the FDA cleared an IND for dual CD19/CD38 CAR T-cell FT839 for a Phase 1/2 basket trial in autoimmune disease.
Preliminary FT819 data in systemic lupus erythematosus and systemic sclerosis showed favorable tolerability with no CRS, ICANS, GvHD, or hypogammaglobulinemia and encouraging clinical activity, while FT836 demonstrated early anti-tumor signals in KRAS wild-type metastatic colorectal cancer without conditioning chemotherapy. Cash, cash equivalents, and investments were $153.8 million at June 30, 2026, a quarterly decrease of $21 million, and operating runway is expected into 2028.
Second-quarter collaboration revenue was $2.1 million, total operating expenses were $33.2 million, and net loss was $30.2 million, or $(0.25) per share, improving from a $(34.1) million loss a year earlier. For the first half of 2026, total operating expenses fell by $14.3 million versus 2025, reflecting 13% lower R&D and 27% lower G&A.
Fate Therapeutics’ Chief Legal and Compliance Officer, Cindy Tahl, reported a sale of 38,800 shares of common stock on August 4, 2026 at a weighted average price of $2.4589 per share, with prices ranging from $2.415 to $2.540.
The shares were sold to cover tax withholding obligations in connection with the vesting of 75,000 shares of common stock underlying RSUs granted on July 29, 2024, through automatic “sell-to-cover” transactions executed under an irrevocable election and not at her discretion. After these transactions, she directly holds 589,355 shares of Fate Therapeutics common stock.
Fate Therapeutics reported that President and CEO Bahram Valamehr sold 43,947 shares of common stock on August 4, 2026 at a weighted average price of $2.4598 per share, with individual trades between $2.415 and $2.540. The sale covered tax withholding arising from vesting of 75,000 RSU-based shares and was automatically executed under an irrevocable sell-to-cover election, not at his discretion. After this transaction, he directly holds 591,815 shares of Fate Therapeutics common stock.
Cindy Tahl filed a notice of proposed sale under Form 144 for 38,800 shares of common stock held at Fidelity Brokerage Services LLC, with an aggregate market value of $95,405.32. The proposed sale is dated August 4, 2026 on NASDAQ.
The shares to be sold were acquired from the issuer on August 3, 2026 through Restricted Stock Vesting as compensation. Over the prior three months, Tahl sold 25,590 common shares on May 20, 2026 for total proceeds of $48,083.61.
Bahram Valamehr provides notice related to potential sales of common stock of FATE. The securities section lists 43,947 common shares, associated with restricted stock vesting on 08/03/2026, with Fidelity Brokerage Services LLC as broker and NASDAQ as the trading market. The filing also reports that during the past three months, on 05/20/2026, 28,946 common shares were sold for $54,482.16.
BlackRock, Inc. filed Amendment No. 8 on a Schedule 13G/A reporting beneficial ownership of 2,194,284 shares of Fate Therapeutics common stock, representing 1.9% of the class as reported on 06/30/2026. The filing lists sole voting and sole dispositive power for 2,194,284 shares. The filing is signed by Spencer Fleming as Managing Director on 07/08/2026.
Fate Therapeutics reported that an entity associated with Redmile Group received a new stock option award linked to board service. The option covers 87,900 shares of common stock at an exercise price of $2.06 per share and expires on June 12, 2036. It was granted to director Michael Lee for his role on the board, but, under Redmile’s policies, he holds it as a nominee for the sole benefit of Redmile, which has the economic and voting rights. The option will vest in full on the earlier of June 12, 2027 or the date of the company’s 2027 annual stockholder meeting, subject to Lee’s continued board service. Redmile and principal Jeremy Green disclaim beneficial ownership except to any pecuniary interest they may have.
Fate Therapeutics director Michael Stewart Lee received a grant of stock options as compensation for his board service. The award covers 87,900 stock options to purchase common shares at an exercise price of $2.06 per share, expiring on June 12, 2036. The options vest in full on the earlier of June 12, 2027 or the company’s 2027 annual stockholders’ meeting, subject to his continued board service. The grant is held by Lee as a nominee for Redmile Group, LLC, which holds the economic and voting rights, and both Lee and Redmile parties disclaim beneficial ownership except to the extent of any pecuniary interest.
Fate Therapeutics director Yuan Xu received a new stock option grant as board compensation. The award covers 87,900 shares of common stock at an exercise price of $2.06 per share and is held directly. Following this grant, Xu holds options on 87,900 underlying shares.
The option vests and becomes exercisable on the earlier of June 12, 2027 or the date of Fate Therapeutics’ 2027 annual stockholder meeting, as long as Xu continues serving on the board. This is a non-employee director equity grant under the company’s compensation policy, not an open-market purchase or sale.